Neuropace
NPCE
22 hedge funds and large institutions have $78.6M invested in Neuropace in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $82M → $78.6M (-$3.4M)
1.51% less ownership
Funds ownership: 70.4% → 68.88% (-1.5%)
8% less funds holding
Funds holding: 24 → 22 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$456K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$369K |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$170K |
| 4 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$97.4K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$38K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.22M |
| 2 |
Millennium Management
New York
|
-$465K |
| 3 |
SG Americas Securities
New York
|
-$118K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$65.2K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$34K |
NPCE Hedge Fund Activity: Q2 2023 in Review
22 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q2 2023, worth a combined $78.6M — down 4.1% from $82M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NPCE and 1 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Morgan Stanley, adding an estimated $456K. The largest seller was Fidelity Investments, cutting an estimated $1.22M.
- 22 institutional investors held Neuropace (NPCE) as of Q2 2023, down from 24 in Q1 2023.
- Funds reported $78.6M of Neuropace stock for Q2 2023, down 4.1% quarter-over-quarter.
- 1 fund opened new Neuropace positions in Q2 2023 and 3 closed out, a net change of -2 holders.
- The largest Neuropace buyer in Q2 2023 was Morgan Stanley, an estimated $456K added.
- The largest Neuropace seller in Q2 2023 was Fidelity Investments, an estimated $1.22M sold.
Based on aggregated 13F filings for Q2 2023.